IntegraGen announces unaudited sales for the first half of 2020. Unaudited sales during the first half of 2020 were EUR 4,706,000, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales was a result of an increase in all sequencing activities, in particular the SeqOIA platform (+33%), activities related to outsourced platforms (+18%), and sequencing services for research and clinical research (+9%). Software and genomic consulting (GeCo) activities were limited due to the pandemic, which notably resulted in the delay of projects.